The initial CAPP2 (Colorectal Adenoma/Carcinoma Prevention Programme 2) trial was funded by multiple sources, including Bayer Pharmaceuticals, which provided administrative support for the follow-up analysis. The authors reported no conflicts of interest.
A daily 600-mg dose of aspirin reduces the cancer burden by about half in these high-risk patients.
Source © jimdeli/Fotolia.com